Compare DexCom, Inc. (DXCM) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? DexCom, Inc. trades at $77.58 (market cap $28.06B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $242.48 (market cap $45.27B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is the larger of the two by market cap. Which is the better fit depends on your goals.
| DXCM | TTWO | |
|---|---|---|
Market Cap | $28.06B | $45.27B |
Sector | Health | Media |
52-Week High | $89.53 | $262.29 |
52-Week Low | $54.84 | $189.69 |
Enterprise Value | $27.03B | $46.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Take-Two Interactive (TTWO) trades at $237.03, down 2.89% on the day, amid mixed technical signals but strong analyst optimism. The stock shows a bullish technical bias with recent price action near support at $235, while fundamentals reveal significant net losses despite revenue growth, heavily influenced by high operating costs. Key developments include the upcoming Q1 FY2027 earnings report on August 7, 2026, and strong pre-order momentum for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch.
The outlook is cautiously optimistic, driven by GTA VI's potential to boost future earnings, with a consensus price target of $302.50 implying substantial upside. However, risks include persistent negative profit margins, elevated debt levels, and execution challenges in monetizing new releases, requiring careful monitoring of upcoming financial results for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
